Axon Enterprise, Inc. (NASDAQ:AXON – Get Free Report) CEO Patrick W. Smith sold 47,314 shares of the company’s stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $400.07, for a total value of $18,928,911.98. Following the completion of the sale, the chief executive officer now directly owns 2,983,802 shares of the company’s stock, valued at approximately $1,193,729,666.14. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Axon Enterprise Stock Performance
Axon Enterprise stock opened at $415.05 on Friday. The company has a debt-to-equity ratio of 0.35, a current ratio of 2.88 and a quick ratio of 2.52. Axon Enterprise, Inc. has a 12 month low of $190.01 and a 12 month high of $415.11. The company has a fifty day moving average price of $361.35 and a two-hundred day moving average price of $322.04. The company has a market cap of $31.32 billion, a PE ratio of 121.36, a P/E/G ratio of 10.59 and a beta of 0.94.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last posted its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, beating the consensus estimate of $1.02 by $0.18. The business had revenue of $504.00 million during the quarter, compared to analyst estimates of $478.35 million. Axon Enterprise had a net margin of 16.06% and a return on equity of 9.34%. The company’s quarterly revenue was up 34.5% on a year-over-year basis. During the same period in the previous year, the business posted $0.80 EPS. Research analysts expect that Axon Enterprise, Inc. will post 1.79 earnings per share for the current year.
Analysts Set New Price Targets
Check Out Our Latest Stock Analysis on Axon Enterprise
Hedge Funds Weigh In On Axon Enterprise
Several institutional investors have recently made changes to their positions in AXON. Avantax Advisory Services Inc. lifted its holdings in shares of Axon Enterprise by 0.8% in the 1st quarter. Avantax Advisory Services Inc. now owns 5,302 shares of the biotechnology company’s stock worth $1,659,000 after purchasing an additional 40 shares during the last quarter. GSA Capital Partners LLP acquired a new position in shares of Axon Enterprise during the first quarter valued at $931,000. Sumitomo Mitsui Trust Holdings Inc. grew its position in shares of Axon Enterprise by 14.8% during the first quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 170,376 shares of the biotechnology company’s stock worth $53,307,000 after acquiring an additional 22,013 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Axon Enterprise by 21.7% in the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 9,153 shares of the biotechnology company’s stock worth $2,693,000 after acquiring an additional 1,634 shares during the period. Finally, Cim LLC acquired a new stake in shares of Axon Enterprise in the 4th quarter worth about $1,409,000. 79.08% of the stock is owned by institutional investors.
Axon Enterprise Company Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
Recommended Stories
- Five stocks we like better than Axon Enterprise
- How to Calculate Inflation Rate
- When Is the Best Time to Invest in Mutual Funds?
- How to Capture the Benefits of Dividend Increases
- Is NVIDIA Stock in a Correction or Consolidation?
- What is a Stock Market Index and How Do You Use Them?
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.